Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Human Clinical Evidence To date, only three small human pilot studies of BPC-157 have been published in peer-reviewed medical literature: Knee Pain Study (2021): A pilot study examined 16 patients with chronic knee pain who received BPC-157 injections
Beau A, Benoit B, Le Barz M, Meugnier E, Penhoat A, Calzada C, Pinteur C, Loizon E, Chanon S, Vieille-Marchiset A, et al
Need Help Billing CPT Code 96372 Correctly
Late phase maturation (weeks 7-12+) Tissue maturation continues beyond acute healing, with collagen cross-linking and fiber organization improving progressively
Trial-Reported Endpoints by Phase Trial Lancet 2021 Phase 2 Duration 26 weeks Population Overweight/obese, no T2D (n=706) Mean Weight Loss 10.8% at 4.5 mg vs 3.0% placebo Trial Lancet 2023 Phase 2 Duration 32 weeks Population T2D + obesity (n=92) Mean Weight Loss 8.1% cagrilintide alone
US$ 23.70
US$ 26.81
US$ 25.14
US$ 21.60
US$ 23.25
US$ 23.38
US$ 23.93
US$ 29.81
US$ 28.60
US$ 27.70
US$ 25.12
US$ 23.04
